Medifast INC 8-K filings

Medifast announced second quarter 2026 results showing a 27.6% revenue decrease to $76.4 million and a net loss of $3.1 million, impacted by a significant drop in active coaches.

Medifast, Inc. announced the rebranding of its lifestyle brand OPTAVIA to Trilivy, a comprehensive metabolic health system, marking a significant corporate transformation.

Medifast, Inc. announced the resignation of its Chief Legal Officer & Corporate Secretary, Jason L. Groves, effective May 29, 2026, with a separation agreement in place.

Medifast, Inc. announced the appointment of Nicholas Johnson as CEO, effective June 1, 2026, succeeding Daniel Chard who will remain Chairman, and the stockholder approval of an amendment to the 2012 Share Incentive Plan.

Medifast announced its first quarter 2026 financial results, reporting a revenue of $76.0 million and a net loss of $2.1 million, or $0.19 per diluted share.

Medifast and Steamboat Capital Partners LLC have entered a Cooperation Agreement, leading to new independent director nominations and a CEO transition plan.

Medifast announces a planned leadership transition with CEO Dan Chard stepping down in June 2026, to be succeeded by new President Nicholas Johnson, alongside the departure of Chief Business Operations Officer Anthony Tyree.

Medifast reported a significant 36.2% revenue decrease to $89.4 million and a net loss of $2.3 million in Q3 2025, primarily due to declining active coaches and GLP-1 medication impact.

Medifast reported a return to net income in Q2 2025 despite a significant revenue drop and continued decline in active coaches.

Medifast, Inc. stockholders approved an amendment to the 2012 Share Incentive Plan, increasing authorized shares by 550,000, and re-elected all nominated directors at the 2025 Annual Meeting.

Medifast's Q1 2025 results reveal a revenue decrease driven by fewer active coaches, as the company focuses on revitalizing its coach and customer base and improving profitability.

Medifast's Q4 and full year 2024 results reveal significant revenue and profit declines, driven by a decrease in active coaches and lower productivity, as the company navigates a changing health and wellness market.

Medifast's third-quarter results show a significant revenue decrease, driven by fewer coaches and lower productivity, while the company focuses on a new strategy including medication support and customized solutions.

Medifast's second quarter 2024 results show a significant revenue decrease, but the company is focusing on strategic changes for long-term growth.

Medifast's shareholders approved an amendment to the 2012 Share Incentive Plan, increasing the authorized shares and updating plan provisions, and re-elected all nominated directors at the 2024 annual meeting.

Medifast's first quarter 2024 results show a substantial revenue decrease, driven by fewer coaches and lower productivity, while the company invests in medical weight loss solutions.

Medifast's Q4 2023 revenue decreased by 43.4% year-over-year, driven by a decline in active coaches and their productivity, while the company initiates a business transformation.